NCT03646331View on ClinicalTrials.gov

Bioequivalence of Imeglimin Tablet Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 3, 2018

Primary Completion Date

September 27, 2018

Study Completion Date

October 2, 2018

Conditions
Bioequivalence
Interventions
DRUG

Imeglimin Reference product

Reference product

DRUG

Imeglimin

Test product (new formulation tablet)

Trial Locations (1)

Unknown

Hammersmith Medicines Research (HMR), London

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT03646331 - Bioequivalence of Imeglimin Tablet Formulations | Biotech Hunter | Biotech Hunter